Nakamura E, Kaneko Y, Takenawa J, Sasaki M
Department of Urology, Sizuoka City Hospital.
Hinyokika Kiyo. 1992 Aug;38(8):913-8.
The development of cisplatin-based chemotherapy has achieved a high cure rate in patients with advanced germ cell tumors (GCT) and it is more important to predict the prognosis of each patient before treatment and select the most suitable regimen of therapy. To date, 4 risk criteria for GCT are presented. From November, 1985 to April, 1991 our treatment protocol for GCT consisted of VAB-6 (vinblastine, actinomycin D, bleomycin, cisplatinum) or PVeBV (vinblastine, etoposide, bleomycin, high-dose cisplatin) as the induction chemotherapy and VIP (etoposide, ifosfamide, cisplatin) as the salvage chemotherapy. In total, 12 patients were entered on this protocol. They were divided into 2 groups based on the actual clinical course. Those who achieved complete remission within 3 cycles of chemotherapy were divided into "good response group" and others were into "poor response group". These results were compared with those classified by the 4 risk criteria. As a result of our study "The Indiana Staging System" seemed to be the most useful.
基于顺铂的化疗发展已使晚期生殖细胞肿瘤（GCT）患者获得了较高的治愈率，且在治疗前预测每位患者的预后并选择最合适的治疗方案更为重要。迄今为止，已提出了4种GCT风险标准。1985年11月至1991年4月，我们的GCT治疗方案包括采用VAB - 6（长春碱、放线菌素D、博来霉素、顺铂）或PVeBV（长春碱、依托泊苷、博来霉素、高剂量顺铂）进行诱导化疗，以及采用VIP（依托泊苷、异环磷酰胺、顺铂）进行挽救化疗。总共有12例患者进入该方案。根据实际临床病程将他们分为2组。在化疗3个周期内实现完全缓解的患者被分为“良好反应组”，其他患者则分为“不良反应组”。将这些结果与根据4种风险标准分类的结果进行比较。我们的研究结果表明，“印第安纳分期系统”似乎是最有用的。
